BR112018008397B1 - Composto, sal farmacêuticamente aceitável e formas cristalinas - Google Patents

Info

Publication number

BR112018008397B1

BR112018008397B1 BR112018008397-6A BR112018008397A BR112018008397B1 BR 112018008397 B1 BR112018008397 B1 BR 112018008397B1 BR 112018008397 A BR112018008397 A BR 112018008397A BR 112018008397 B1 BR112018008397 B1 BR 112018008397B1

Authority

BR

Brazil

Prior art keywords

methyl

compound

formula

pyrazin

dihydroimidazo

Prior art date

2015-11-09

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 372
• 150000003839 salts Chemical class 0.000 title claims abstract description 161
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 54
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid group Chemical group C(CCCCC(=O)O)(=O)O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 52
• HVIGNZUDBVLTLU-MRXNPFEDSA-N (6R)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C[C@@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F HVIGNZUDBVLTLU-MRXNPFEDSA-N 0.000 claims description 51
• 239000001361 adipic acid Substances 0.000 claims description 26
• 235000011037 adipic acid Nutrition 0.000 claims description 26
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
• 239000013078 crystal Substances 0.000 claims description 6
• 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 5
• 239000000843 powder Substances 0.000 claims description 5
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 abstract description 112
• 238000000034 method Methods 0.000 abstract description 90
• 238000011282 treatment Methods 0.000 abstract description 90
• 201000011510 cancer Diseases 0.000 abstract description 64
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 14
• 238000002360 preparation method Methods 0.000 abstract description 10
• 230000008569 process Effects 0.000 abstract description 6
• 239000000543 intermediate Substances 0.000 description 232
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 193
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 160
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 153
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 132
• -1 6-methylpyridin-2-yl Chemical group 0.000 description 123
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 102
• 239000000203 mixture Substances 0.000 description 98
• 239000007787 solid Substances 0.000 description 96
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 90
• 239000000243 solution Substances 0.000 description 84
• 239000000377 silicon dioxide Substances 0.000 description 73
• 210000004027 cell Anatomy 0.000 description 72
• 239000012043 crude product Substances 0.000 description 71
• 229910052739 hydrogen Inorganic materials 0.000 description 68
• 239000001257 hydrogen Substances 0.000 description 68
• 238000005160 1H NMR spectroscopy Methods 0.000 description 67
• 229910052757 nitrogen Inorganic materials 0.000 description 66
• 229960005419 nitrogen Drugs 0.000 description 66
• 239000000460 chlorine Chemical group 0.000 description 61
• 239000011541 reaction mixture Substances 0.000 description 60
• 229910052801 chlorine Chemical group 0.000 description 59
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 58
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 56
• 150000002431 hydrogen Chemical group 0.000 description 55
• 238000003818 flash chromatography Methods 0.000 description 53
• 239000002904 solvent Substances 0.000 description 53
• 238000010828 elution Methods 0.000 description 52
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 51
• 241001465754 Metazoa Species 0.000 description 50
• 229910052799 carbon Inorganic materials 0.000 description 50
• 238000006243 chemical reaction Methods 0.000 description 50
• 125000001424 substituent group Chemical group 0.000 description 50
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 49
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
• 235000019439 ethyl acetate Nutrition 0.000 description 43
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 42
• 241000282414 Homo sapiens Species 0.000 description 41
• 150000001721 carbon Chemical group 0.000 description 41
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 40
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 40
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 40
• 230000002829 reductive effect Effects 0.000 description 40
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 40
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 39
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
• 125000004432 carbon atom Chemical group C* 0.000 description 37
• 108090000623 proteins and genes Proteins 0.000 description 37
• 239000000047 product Substances 0.000 description 36
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 35
• 239000011737 fluorine Substances 0.000 description 35
• 229910052731 fluorine Inorganic materials 0.000 description 35
• 239000007832 Na2SO4 Substances 0.000 description 34
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 34
• 229910052938 sodium sulfate Inorganic materials 0.000 description 34
• 235000011152 sodium sulphate Nutrition 0.000 description 34
• 239000000523 sample Substances 0.000 description 33
• 101150105104 Kras gene Proteins 0.000 description 32
• 239000002246 antineoplastic agent Substances 0.000 description 31
• 150000007523 nucleic acids Chemical class 0.000 description 31
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 31
• 238000003199 nucleic acid amplification method Methods 0.000 description 30
• 239000012044 organic layer Substances 0.000 description 30
• 102100030708 GTPase KRas Human genes 0.000 description 29
• 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 29
• 230000003321 amplification Effects 0.000 description 29
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 29
• 230000035772 mutation Effects 0.000 description 29
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 28
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 28
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
• 229910000024 caesium carbonate Inorganic materials 0.000 description 28
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 28
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
• 239000002253 acid Substances 0.000 description 27
• 239000003814 drug Substances 0.000 description 27
• 239000003112 inhibitor Substances 0.000 description 27
• 229950010746 selumetinib Drugs 0.000 description 27
• 239000002585 base Substances 0.000 description 26
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 26
• 108020004707 nucleic acids Proteins 0.000 description 26
• 102000039446 nucleic acids Human genes 0.000 description 26
• 125000006239 protecting group Chemical group 0.000 description 25
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 24
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
• 238000004519 manufacturing process Methods 0.000 description 22
• 210000004881 tumor cell Anatomy 0.000 description 22
• 201000010099 disease Diseases 0.000 description 21
• 238000003752 polymerase chain reaction Methods 0.000 description 21
• 125000004076 pyridyl group Chemical group 0.000 description 21
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 20
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 20
• JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 description 19
• 230000000694 effects Effects 0.000 description 19
• 239000003921 oil Substances 0.000 description 19
• 235000019198 oils Nutrition 0.000 description 19
• 239000012074 organic phase Substances 0.000 description 19
• 238000003556 assay Methods 0.000 description 18
• 108020004414 DNA Proteins 0.000 description 17
• 238000002953 preparative HPLC Methods 0.000 description 17
• 239000003480 eluent Substances 0.000 description 16
• 201000001441 melanoma Diseases 0.000 description 16
• 229940002612 prodrug Drugs 0.000 description 16
• 239000000651 prodrug Substances 0.000 description 16
• 125000000714 pyrimidinyl group Chemical group 0.000 description 16
• 229910000104 sodium hydride Inorganic materials 0.000 description 16
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 15
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 15
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 15
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
• 229910000027 potassium carbonate Inorganic materials 0.000 description 15
• 235000015320 potassium carbonate Nutrition 0.000 description 15
• 238000000746 purification Methods 0.000 description 15
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
• 239000000090 biomarker Substances 0.000 description 14
• 238000001914 filtration Methods 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 14
• 239000003208 petroleum Substances 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 13
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 13
• 230000017095 negative regulation of cell growth Effects 0.000 description 13
• 230000004083 survival effect Effects 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
• 239000002552 dosage form Substances 0.000 description 12
• 239000012041 precatalyst Substances 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 230000019491 signal transduction Effects 0.000 description 12
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
• 239000004480 active ingredient Substances 0.000 description 11
• 239000003085 diluting agent Substances 0.000 description 11
• 208000035475 disorder Diseases 0.000 description 11
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
• 229910052736 halogen Inorganic materials 0.000 description 11
• 150000002367 halogens Chemical class 0.000 description 11
• 230000002401 inhibitory effect Effects 0.000 description 11
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
• 230000037361 pathway Effects 0.000 description 11
• 206010009944 Colon cancer Diseases 0.000 description 10
• 102000043136 MAP kinase family Human genes 0.000 description 10
• 108091054455 MAP kinase family Proteins 0.000 description 10
• 208000003019 Neurofibromatosis 1 Diseases 0.000 description 10
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 10
• 125000000217 alkyl group Chemical group 0.000 description 10
• 238000013459 approach Methods 0.000 description 10
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 239000010410 layer Substances 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• 239000002244 precipitate Substances 0.000 description 10
• 102000016914 ras Proteins Human genes 0.000 description 10
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 9
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
• 241000282320 Panthera leo Species 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 238000000113 differential scanning calorimetry Methods 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 230000001575 pathological effect Effects 0.000 description 9
• 230000002265 prevention Effects 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 229920006395 saturated elastomer Polymers 0.000 description 9
• 239000003643 water by type Substances 0.000 description 9
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 8
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 8
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 8
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
• 201000005969 Uveal melanoma Diseases 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 125000002252 acyl group Chemical group 0.000 description 8
• 239000003054 catalyst Substances 0.000 description 8
• 231100000673 dose–response relationship Toxicity 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 230000003463 hyperproliferative effect Effects 0.000 description 8
• 238000005259 measurement Methods 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 239000012312 sodium hydride Substances 0.000 description 8
• 239000000758 substrate Substances 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• 238000005292 vacuum distillation Methods 0.000 description 8
• SGPPRSHLSJWWBC-AWEZNQCLSA-N (6S)-7-[(3-chlorophenyl)methyl]-6-methyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(C[C@@H]2C)C=C(N=3)C2=NC(=NC=C2)NC2=CC=NN2C)=O)C=CC=1 SGPPRSHLSJWWBC-AWEZNQCLSA-N 0.000 description 7
• 229940124647 MEK inhibitor Drugs 0.000 description 7
• 108091034117 Oligonucleotide Proteins 0.000 description 7
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
• 230000001028 anti-proliverative effect Effects 0.000 description 7
• 239000012131 assay buffer Substances 0.000 description 7
• 208000020790 biliary tract neoplasm Diseases 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• IWMMXPNBCHCFCY-UHFFFAOYSA-M dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;palladium(2+);2-phenylethanamine;chloride Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 IWMMXPNBCHCFCY-UHFFFAOYSA-M 0.000 description 7
• 150000002148 esters Chemical class 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
• 235000019341 magnesium sulphate Nutrition 0.000 description 7
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
• 239000011159 matrix material Substances 0.000 description 7
• 239000002773 nucleotide Substances 0.000 description 7
• 125000003729 nucleotide group Chemical group 0.000 description 7
• 201000002528 pancreatic cancer Diseases 0.000 description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 description 7
• 102000054765 polymorphisms of proteins Human genes 0.000 description 7
• 238000009097 single-agent therapy Methods 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• 230000004614 tumor growth Effects 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 108700028369 Alleles Proteins 0.000 description 6
• 102100039788 GTPase NRas Human genes 0.000 description 6
• 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 6
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 6
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• QMAGZXWGRSTRAT-UHFFFAOYSA-N ethyl 1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=CN1COCC[Si](C)(C)C QMAGZXWGRSTRAT-UHFFFAOYSA-N 0.000 description 6
• 239000000706 filtrate Substances 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 125000005843 halogen group Chemical group 0.000 description 6
• 238000010438 heat treatment Methods 0.000 description 6
• 238000004949 mass spectrometry Methods 0.000 description 6
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 6
• LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
• 230000002195 synergetic effect Effects 0.000 description 6
• NSXVPQOGAZOTJR-MRXNPFEDSA-N (6R)-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound COC[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(=CC=C1)C(F)F)C1=C(C)C=NC(NC2=CC=NN2C)=N1 NSXVPQOGAZOTJR-MRXNPFEDSA-N 0.000 description 5
• URIMKYWVDFMVHO-LURJTMIESA-N (6S)-2-(2-chloropyrimidin-4-yl)-6-methyl-6,7-dihydro-5H-imidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1)C1=CC=NC(Cl)=N1 URIMKYWVDFMVHO-LURJTMIESA-N 0.000 description 5
• WBWWMWKOTILXSS-LBPRGKRZSA-N (6S)-2-[5-chloro-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[(3,4-difluorophenyl)methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C(=NC(=NC=1)NC1=CC=NN1C)C=1N=C2N(C[C@@H](N(C2=O)CC2=CC(=C(C=C2)F)F)C)C=1 WBWWMWKOTILXSS-LBPRGKRZSA-N 0.000 description 5
• IQYSVSPDVOAQCS-AWEZNQCLSA-N (6S)-2-[5-chloro-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[(3-methoxyphenyl)methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound COC1=CC=CC(CN2[C@@H](C)CN3C=C(N=C3C2=O)C2=C(Cl)C=NC(NC3=CC=NN3C)=N2)=C1 IQYSVSPDVOAQCS-AWEZNQCLSA-N 0.000 description 5
• GCQOVMAAPRLUDR-LBPRGKRZSA-N (6S)-2-[5-chloro-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(=CC=C1)C(F)F)C1=C(Cl)C=NC(NC2=CC=NN2C)=N1 GCQOVMAAPRLUDR-LBPRGKRZSA-N 0.000 description 5
• GSNUZUIWBUUZPG-ZDUSSCGKSA-N (6S)-7-[(3,4-difluorophenyl)methyl]-6-methyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(F)=C(F)C=C1)C1=CC=NC(NC2=CC=NN2C)=N1 GSNUZUIWBUUZPG-ZDUSSCGKSA-N 0.000 description 5
• UOYGUKNWRPYQIB-ZDUSSCGKSA-N (6S)-7-[(3-chloro-4-fluorophenyl)methyl]-6-methyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(C[C@@H]2C)C=C(N=3)C2=NC(=NC=C2)NC2=CC=NN2C)=O)C=CC=1F UOYGUKNWRPYQIB-ZDUSSCGKSA-N 0.000 description 5
• NXDOCYPZIGXILP-AWEZNQCLSA-N (6S)-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC(C1=CC=CC(=N1)CN1C(C=2N(C[C@@H]1C)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)F NXDOCYPZIGXILP-AWEZNQCLSA-N 0.000 description 5
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 5
• LDWCHEJBPZNGIS-UHFFFAOYSA-N 2-(2-chloro-5-methylpyrimidin-4-yl)-6,7-dihydro-5H-imidazo[1,2-a]pyrazin-8-one Chemical compound CC1=C(N=C(Cl)N=C1)C1=CN2CCNC(=O)C2=N1 LDWCHEJBPZNGIS-UHFFFAOYSA-N 0.000 description 5
• GBKAYGXNHRHDFP-UHFFFAOYSA-N 2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[(6-methylpyridin-2-yl)methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound CN1N=CC=C1NC1=NC=CC(=N1)C=1N=C2N(CCN(C2=O)CC2=NC(=CC=C2)C)C=1 GBKAYGXNHRHDFP-UHFFFAOYSA-N 0.000 description 5
• ZAOUAONJSHJDIO-UHFFFAOYSA-N 2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound CC=1C(=NC(=NC=1)NC1=CC=NN1C)C=1N=C2N(CCN(C2=O)CC2=NC(=CC=C2)C(F)(F)F)C=1 ZAOUAONJSHJDIO-UHFFFAOYSA-N 0.000 description 5
• RBBNHPCATVVAJB-UHFFFAOYSA-N 7-[(3-chloro-4-fluorophenyl)methyl]-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(CC2)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F RBBNHPCATVVAJB-UHFFFAOYSA-N 0.000 description 5
• FMZILARCUYGTNR-UHFFFAOYSA-N 7-[(3-chlorophenyl)methyl]-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(CC2)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1 FMZILARCUYGTNR-UHFFFAOYSA-N 0.000 description 5
• OBCKTAPOTATUEO-UHFFFAOYSA-N 7-[[3-(difluoromethyl)phenyl]methyl]-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC(C=1C=C(CN2C(C=3N(CC2)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1)F OBCKTAPOTATUEO-UHFFFAOYSA-N 0.000 description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• 230000001740 anti-invasion Effects 0.000 description 5
• 230000000259 anti-tumor effect Effects 0.000 description 5
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• CYPZPQKFCFTIHH-UHFFFAOYSA-N ethyl 4-bromo-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC(Br)=CN1COCC[Si](C)(C)C CYPZPQKFCFTIHH-UHFFFAOYSA-N 0.000 description 5
• KPSPYULVUMEFRQ-UHFFFAOYSA-N ethyl 5-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-2-carboxylate Chemical compound ClC1=NC=C(C(=N1)C=1N=C(NC=1)C(=O)OCC)C KPSPYULVUMEFRQ-UHFFFAOYSA-N 0.000 description 5
• 239000000796 flavoring agent Substances 0.000 description 5
• 231100000590 oncogenic Toxicity 0.000 description 5
• 230000002246 oncogenic effect Effects 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 230000004043 responsiveness Effects 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 239000003765 sweetening agent Substances 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• WMZHUQPUDOWPQA-MRVPVSSYSA-N (6R)-2-(2-chloro-5-methylpyrimidin-4-yl)-6-(methoxymethyl)-6,7-dihydro-5H-imidazo[1,2-a]pyrazin-8-one Chemical compound COC[C@H]1CN2C=C(N=C2C(=O)N1)C1=C(C)C=NC(Cl)=N1 WMZHUQPUDOWPQA-MRVPVSSYSA-N 0.000 description 4
• OWNNJXIFOCUDNQ-NSHDSACASA-N (6S)-2-(2,5-dichloropyrimidin-4-yl)-7-[(3-methoxyphenyl)methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(C[C@@H](N(C2=O)CC2=CC(=CC=C2)OC)C)C=1)Cl OWNNJXIFOCUDNQ-NSHDSACASA-N 0.000 description 4
• MFXVDDUSPPQUJQ-AWEZNQCLSA-N (6S)-2-[5-chloro-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-6-methyl-7-[(6-methylpyridin-2-yl)methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(C)=CC=C1)C1=C(Cl)C=NC(NC2=CC=NN2C)=N1 MFXVDDUSPPQUJQ-AWEZNQCLSA-N 0.000 description 4
• ZKAGFYDLIKYEGI-NSHDSACASA-N (6S)-2-[5-chloro-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-6-methyl-7-[[2-(trifluoromethyl)pyrimidin-4-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC=NC(=N1)C(F)(F)F)C1=C(Cl)C=NC(NC2=CC=NN2C)=N1 ZKAGFYDLIKYEGI-NSHDSACASA-N 0.000 description 4
• BGPRQBFCHKTOSX-LBPRGKRZSA-N (6S)-2-[5-chloro-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-6-methyl-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(=CC=C1)C(F)(F)F)C1=C(Cl)C=NC(NC2=CC=NN2C)=N1 BGPRQBFCHKTOSX-LBPRGKRZSA-N 0.000 description 4
• BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 4
• DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 4
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical class C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 4
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• IUXXMSYHFUPWFT-UHFFFAOYSA-N 6-(difluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)C1=CC=CC(C=O)=N1 IUXXMSYHFUPWFT-UHFFFAOYSA-N 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• 238000005481 NMR spectroscopy Methods 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 108091008611 Protein Kinase B Proteins 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 239000012391 XPhos Pd G2 Substances 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 229910021529 ammonia Inorganic materials 0.000 description 4
• 239000008346 aqueous phase Substances 0.000 description 4
• 125000003435 aroyl group Chemical group 0.000 description 4
• 201000009036 biliary tract cancer Diseases 0.000 description 4
• 239000012472 biological sample Substances 0.000 description 4
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000002512 chemotherapy Methods 0.000 description 4
• 125000001309 chloro group Chemical group Cl* 0.000 description 4
• 239000012230 colorless oil Substances 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 238000001704 evaporation Methods 0.000 description 4
• 230000008020 evaporation Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 235000003599 food sweetener Nutrition 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 230000009036 growth inhibition Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• 229910021421 monocrystalline silicon Inorganic materials 0.000 description 4
• 238000005191 phase separation Methods 0.000 description 4
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000004853 protein function Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• BDYKSIVIAYZBAJ-RWNHWRGESA-N tert-butyl (4S)-4-(methoxymethyl)-2-oxooxathiazolidine-3-carboxylate Chemical compound COC[C@@H]1N(S(OC1)=O)C(=O)OC(C)(C)C BDYKSIVIAYZBAJ-RWNHWRGESA-N 0.000 description 4
• CMWJWKLWQJMPMM-SSDOTTSWSA-N tert-butyl n-[(2r)-1-hydroxy-3-methoxypropan-2-yl]carbamate Chemical compound COC[C@@H](CO)NC(=O)OC(C)(C)C CMWJWKLWQJMPMM-SSDOTTSWSA-N 0.000 description 4
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
• DRPYDUUPNVEQCA-CYBMUJFWSA-N (6R)-2-(2-chloro-5-methylpyrimidin-4-yl)-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-6-(methoxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(C[C@@H](N(C2=O)CC2=NC(=CC=C2)C(F)F)COC)C=1)C DRPYDUUPNVEQCA-CYBMUJFWSA-N 0.000 description 3
• TWLKKKPCUYCTQN-MRXNPFEDSA-N (6R)-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound COC[C@@H]1N(C(C=2N(C1)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)CC1=NC(=CC=C1)C(F)(F)F TWLKKKPCUYCTQN-MRXNPFEDSA-N 0.000 description 3
• DZQCUGHBICCEOR-CQSZACIVSA-N (6R)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1N(C(C=2N(C1)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)CC1=NC(=CC=C1)C(F)(F)F DZQCUGHBICCEOR-CQSZACIVSA-N 0.000 description 3
• LWWMAGSXIWGMEF-GOSISDBHSA-N (6R)-7-[(3,5-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C[C@@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=C(C=1)F LWWMAGSXIWGMEF-GOSISDBHSA-N 0.000 description 3
• NXDOCYPZIGXILP-CQSZACIVSA-N (6R)-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC(C1=CC=CC(=N1)CN1C(C=2N(C[C@H]1C)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)F NXDOCYPZIGXILP-CQSZACIVSA-N 0.000 description 3
• KZYQUJKEZMIDFS-NSHDSACASA-N (6S)-2-(2,5-dichloropyrimidin-4-yl)-6-methyl-7-[(6-methylpyridin-2-yl)methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(C)=CC=C1)C1=C(Cl)C=NC(Cl)=N1 KZYQUJKEZMIDFS-NSHDSACASA-N 0.000 description 3
• GXMXMBPKAYHBKF-QMMMGPOBSA-N (6S)-2-(2,5-dichloropyrimidin-4-yl)-6-methyl-7-[[2-(trifluoromethyl)pyrimidin-4-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC=NC(=N1)C(F)(F)F)C1=C(Cl)C=NC(Cl)=N1 GXMXMBPKAYHBKF-QMMMGPOBSA-N 0.000 description 3
• SDXRFQIMGCUZLK-VIFPVBQESA-N (6S)-2-(2,5-dichloropyrimidin-4-yl)-6-methyl-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(=CC=C1)C(F)(F)F)C1=C(Cl)C=NC(Cl)=N1 SDXRFQIMGCUZLK-VIFPVBQESA-N 0.000 description 3
• MRAXBWLWFQFYFX-VIFPVBQESA-N (6S)-2-(2,5-dichloropyrimidin-4-yl)-7-[(3,4-difluorophenyl)methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(F)=C(F)C=C1)C1=C(Cl)C=NC(Cl)=N1 MRAXBWLWFQFYFX-VIFPVBQESA-N 0.000 description 3
• MBZOMTBMNLNGIE-VIFPVBQESA-N (6S)-2-(2,5-dichloropyrimidin-4-yl)-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=NC(=CC=C1)C(F)F)C1=C(Cl)C=NC(Cl)=N1 MBZOMTBMNLNGIE-VIFPVBQESA-N 0.000 description 3
• CNXPSOBFMZNDMO-AWEZNQCLSA-N (6S)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[2-(trifluoromethyl)pyridin-4-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(=NC=C1)C(F)(F)F)C1=C(C)C=NC(NC2=CC=NN2C)=N1 CNXPSOBFMZNDMO-AWEZNQCLSA-N 0.000 description 3
• JYMMADGLHIVIQW-ZDUSSCGKSA-N (6S)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[2-(trifluoromethyl)pyrimidin-4-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC=NC(=N1)C(F)(F)F)C1=C(C)C=NC(NC2=CC=NN2C)=N1 JYMMADGLHIVIQW-ZDUSSCGKSA-N 0.000 description 3
• FALKKTXIPCIJMU-AWEZNQCLSA-N (6S)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[4-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@@H]1N(C(C=2N(C1)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)CC1=NC=CC(=C1)C(F)(F)F FALKKTXIPCIJMU-AWEZNQCLSA-N 0.000 description 3
• DZQCUGHBICCEOR-AWEZNQCLSA-N (6S)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@@H]1N(C(C=2N(C1)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)CC1=NC(=CC=C1)C(F)(F)F DZQCUGHBICCEOR-AWEZNQCLSA-N 0.000 description 3
• JKEWFGHBOQHABX-ZDUSSCGKSA-N (6S)-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-7-[[6-(trifluoromethyl)pyrimidin-4-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(=NC=N1)C(F)(F)F)C1=C(C)C=NC(NC2=CC=NN2C)=N1 JKEWFGHBOQHABX-ZDUSSCGKSA-N 0.000 description 3
• HVIGNZUDBVLTLU-INIZCTEOSA-N (6S)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C[C@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F HVIGNZUDBVLTLU-INIZCTEOSA-N 0.000 description 3
• MEAVDGTVFNUSBJ-HNNXBMFYSA-N (6S)-7-[(3-chlorophenyl)methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(Cl)=CC=C1)C1=C(C)C=NC(NC2=CC=NN2C)=N1 MEAVDGTVFNUSBJ-HNNXBMFYSA-N 0.000 description 3
• VTWRYQNQNQTDJU-INIZCTEOSA-N (6S)-7-[(3-methoxyphenyl)methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound COC=1C=C(CN2C(C=3N(C[C@@H]2C)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1 VTWRYQNQNQTDJU-INIZCTEOSA-N 0.000 description 3
• CHIZSKFEQQPYIG-HNNXBMFYSA-N (6S)-7-[(4-fluoro-3-methoxyphenyl)methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC1=C(C=C(CN2C(C=3N(C[C@@H]2C)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=C1)OC CHIZSKFEQQPYIG-HNNXBMFYSA-N 0.000 description 3
• BQDAMEBIHXFYOG-AWEZNQCLSA-N (6S)-7-[[4-(difluoromethyl)pyridin-2-yl]methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC(C1=CC(=NC=C1)CN1C(C=2N(C[C@@H]1C)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)F BQDAMEBIHXFYOG-AWEZNQCLSA-N 0.000 description 3
• OAMHLBYJJJGRFL-UHFFFAOYSA-N 2-(2-chloro-5-methylpyrimidin-4-yl)-7-[(3-chlorophenyl)methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound CC1=C(N=C(Cl)N=C1)C1=CN2CCN(CC3=CC(Cl)=CC=C3)C(=O)C2=N1 OAMHLBYJJJGRFL-UHFFFAOYSA-N 0.000 description 3
• WGGCDMUJCGXYHK-UHFFFAOYSA-N 2-(2-chloro-5-methylpyrimidin-4-yl)-7-[[3-(difluoromethyl)phenyl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(CCN(C2=O)CC2=CC(=CC=C2)C(F)F)C=1)C WGGCDMUJCGXYHK-UHFFFAOYSA-N 0.000 description 3
• VVHPUWBQWAQHEQ-UHFFFAOYSA-N 2-(2-chloro-5-methylpyrimidin-4-yl)-7-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(CCN(C2=O)CC2=NC(=CC=C2)C(F)(F)F)C=1)C VVHPUWBQWAQHEQ-UHFFFAOYSA-N 0.000 description 3
• ZTBGDNNRDRISQZ-UHFFFAOYSA-N 2-bromo-6-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=CC(Br)=N1 ZTBGDNNRDRISQZ-UHFFFAOYSA-N 0.000 description 3
• UGRKYDRCMMQFKY-UHFFFAOYSA-N 2-bromo-7-[(6-methylpyridin-2-yl)methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound CC1=CC=CC(CN2CCN3C=C(Br)N=C3C2=O)=N1 UGRKYDRCMMQFKY-UHFFFAOYSA-N 0.000 description 3
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
• PCHZBECNJKFJEB-UHFFFAOYSA-N 6-(difluoromethyl)-N-methoxy-N-methylpyridine-2-carboxamide Chemical compound FC(C1=CC=CC(=N1)C(=O)N(C)OC)F PCHZBECNJKFJEB-UHFFFAOYSA-N 0.000 description 3
• CQOXJYFTHXMTNS-UHFFFAOYSA-N 6-(difluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(F)F)=N1 CQOXJYFTHXMTNS-UHFFFAOYSA-N 0.000 description 3
• GGHDHMVFBOLCFR-UHFFFAOYSA-N 7-[(3,4-difluorophenyl)methyl]-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(CC2)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F GGHDHMVFBOLCFR-UHFFFAOYSA-N 0.000 description 3
• PNMILQMFKJBQNK-UHFFFAOYSA-N 7-[(3-chloro-4-fluorophenyl)methyl]-2-(2-chloro-5-methylpyrimidin-4-yl)-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(CC2)C=C(N=3)C2=NC(=NC=C2C)Cl)=O)C=CC=1F PNMILQMFKJBQNK-UHFFFAOYSA-N 0.000 description 3
• NTXAYWJMXPVFRU-UHFFFAOYSA-N 7-[(6-methylpyridin-2-yl)methyl]-2-(2-methylsulfonylpyrimidin-4-yl)-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound CC1=CC=CC(=N1)CN1C(C=2N(CC1)C=C(N=2)C1=NC(=NC=C1)S(=O)(=O)C)=O NTXAYWJMXPVFRU-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 230000001594 aberrant effect Effects 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 235000019270 ammonium chloride Nutrition 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 239000011260 aqueous acid Substances 0.000 description 3
• 239000007900 aqueous suspension Substances 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 210000003445 biliary tract Anatomy 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 229910052796 boron Inorganic materials 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 239000013058 crude material Substances 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
• 238000009509 drug development Methods 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• BHTFNUCJZGWQNU-UHFFFAOYSA-N ethyl 1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]imidazole-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCCN1C(=NC=C1)C(=O)OCC BHTFNUCJZGWQNU-UHFFFAOYSA-N 0.000 description 3
• UHYNYIGCGVDBTC-UHFFFAOYSA-N ethyl 1h-imidazole-2-carboxylate Chemical compound CCOC(=O)C1=NC=CN1 UHYNYIGCGVDBTC-UHFFFAOYSA-N 0.000 description 3
• ULUULYURYMLTKS-UHFFFAOYSA-N ethyl 5-(2,5-dichloropyrimidin-4-yl)-1H-imidazole-2-carboxylate Chemical compound ClC1=NC=C(C(=N1)C=1N=C(NC=1)C(=O)OCC)Cl ULUULYURYMLTKS-UHFFFAOYSA-N 0.000 description 3
• UFVXAJVQXHAGDA-UHFFFAOYSA-N ethyl 5-(2-chloropyrimidin-4-yl)-1H-imidazole-2-carboxylate Chemical compound ClC1=NC=CC(=N1)C=1N=C(NC=1)C(=O)OCC UFVXAJVQXHAGDA-UHFFFAOYSA-N 0.000 description 3
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 238000005984 hydrogenation reaction Methods 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 3
• 229960004592 isopropanol Drugs 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• YGMCFQRXTSGTNU-UHFFFAOYSA-N methyl 6-(difluoromethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C(F)F)=N1 YGMCFQRXTSGTNU-UHFFFAOYSA-N 0.000 description 3
• CUHWSTDKNWOEFE-UHFFFAOYSA-N n-(2-methylpyrazol-3-yl)formamide Chemical compound CN1N=CC=C1NC=O CUHWSTDKNWOEFE-UHFFFAOYSA-N 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 239000013643 reference control Substances 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 235000017550 sodium carbonate Nutrition 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• ORWHXHCSDYWSCI-ZETCQYMHSA-N tert-butyl (4S)-4-(methoxymethyl)-2,2-dioxooxathiazolidine-3-carboxylate Chemical compound COC[C@H]1COS(=O)(=O)N1C(=O)OC(C)(C)C ORWHXHCSDYWSCI-ZETCQYMHSA-N 0.000 description 3
• DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 3
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
• 239000003039 volatile agent Substances 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• DHPAIROIAXACNO-CYBMUJFWSA-N (6R)-2-(2-chloro-5-methylpyrimidin-4-yl)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(C[C@@H](N(C2=O)CC2=CC(=C(C=C2)F)F)COC)C=1)C DHPAIROIAXACNO-CYBMUJFWSA-N 0.000 description 2
• HFCWXRXMAJPTPI-OAHLLOKOSA-N (6R)-2-(2-chloro-5-methylpyrimidin-4-yl)-7-[(3-chlorophenyl)methyl]-6-(methoxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(C[C@@H](N(C2=O)CC2=CC(=CC=C2)Cl)COC)C=1)C HFCWXRXMAJPTPI-OAHLLOKOSA-N 0.000 description 2
• SOSWEHYPQGUUTE-GOSISDBHSA-N (6R)-7-[(3-chlorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(C[C@@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1 SOSWEHYPQGUUTE-GOSISDBHSA-N 0.000 description 2
• OWPHFRAKUXEJOP-JTQLQIEISA-N (6S)-2-(2-chloropyrimidin-4-yl)-7-[(3,4-difluorophenyl)methyl]-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=CC(=N1)C=1N=C2N(C[C@@H](N(C2=O)CC2=CC(=C(C=C2)F)F)C)C=1 OWPHFRAKUXEJOP-JTQLQIEISA-N 0.000 description 2
• KIATUHOPGBDHPE-JTQLQIEISA-N (6S)-7-[(3-chloro-4-fluorophenyl)methyl]-2-(2-chloropyrimidin-4-yl)-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(C[C@@H]2C)C=C(N=3)C2=NC(=NC=C2)Cl)=O)C=CC=1F KIATUHOPGBDHPE-JTQLQIEISA-N 0.000 description 2
• AHDZGSGBBVDRHZ-NSHDSACASA-N (6S)-7-[(3-chlorophenyl)methyl]-2-(2-chloropyrimidin-4-yl)-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(Cl)=CC=C1)C1=CC=NC(Cl)=N1 AHDZGSGBBVDRHZ-NSHDSACASA-N 0.000 description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• GTZKBAWQLSBLJP-UHFFFAOYSA-N 1-(2-aminoethyl)-4-(2-chloro-5-methylpyrimidin-4-yl)imidazole-2-carboxylic acid Chemical compound Cc1cnc(Cl)nc1-c1cn(CCN)c(n1)C(O)=O GTZKBAWQLSBLJP-UHFFFAOYSA-N 0.000 description 2
• LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 2
• PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
• ACSULCXIPYAPAK-UHFFFAOYSA-N 2-(2-chloro-5-methylpyrimidin-4-yl)-7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound ClC1=NC=C(C(=N1)C=1N=C2N(CCN(C2=O)CC2=NC(=CC=C2)C(F)F)C=1)C ACSULCXIPYAPAK-UHFFFAOYSA-N 0.000 description 2
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
• WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
• JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 2
• OMFVRHWVFINADV-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=N1 OMFVRHWVFINADV-UHFFFAOYSA-N 0.000 description 2
• AHISYUZBWDSPQL-UHFFFAOYSA-N 6-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=CC(C=O)=N1 AHISYUZBWDSPQL-UHFFFAOYSA-N 0.000 description 2
• HVIKHILUNVVPBI-UHFFFAOYSA-N 7-[(6-methylpyridin-2-yl)methyl]-2-(2-methylsulfanylpyrimidin-4-yl)-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound CC1=CC=CC(=N1)CN1C(C=2N(CC1)C=C(N=2)C1=NC(=NC=C1)SC)=O HVIKHILUNVVPBI-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• LYGVXQAHDGMNTQ-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1N=C(N(C=1)COCC[Si](C)(C)C)C(=O)OCC)C Chemical compound ClC1=NC=C(C(=N1)C=1N=C(N(C=1)COCC[Si](C)(C)C)C(=O)OCC)C LYGVXQAHDGMNTQ-UHFFFAOYSA-N 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 239000012824 ERK inhibitor Substances 0.000 description 2
• 241000400611 Eucalyptus deanei Species 0.000 description 2
• UWOPPUCACWLCPT-UHFFFAOYSA-N FC(C1=CC=CC(=N1)C(=O)Cl)F Chemical compound FC(C1=CC=CC(=N1)C(=O)Cl)F UWOPPUCACWLCPT-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 206010069755 K-ras gene mutation Diseases 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 206010036790 Productive cough Diseases 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 238000011394 anticancer treatment Methods 0.000 description 2
• 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 2
• 125000005002 aryl methyl group Chemical group 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000035578 autophosphorylation Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 235000015165 citric acid Nutrition 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 239000002178 crystalline material Substances 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 238000001647 drug administration Methods 0.000 description 2
• 238000009510 drug design Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• TZLVQAOKJUBWJO-UHFFFAOYSA-N ethyl 1-(2-aminoethyl)-4-bromoimidazole-2-carboxylate dihydrochloride Chemical compound Cl.Cl.CCOC(=O)c1nc(Br)cn1CCN TZLVQAOKJUBWJO-UHFFFAOYSA-N 0.000 description 2
• GGDMMSODIFXTQE-NSHDSACASA-N ethyl 4-(2-chloropyrimidin-4-yl)-1-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]imidazole-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)N[C@H](CN1C(=NC(=C1)C1=NC(=NC=C1)Cl)C(=O)OCC)C GGDMMSODIFXTQE-NSHDSACASA-N 0.000 description 2
• KPQDYWHBSBKWQM-UHFFFAOYSA-N ethyl 4-bromo-1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]imidazole-2-carboxylate Chemical compound BrC=1N=C(N(C=1)CCNC(=O)OC(C)(C)C)C(=O)OCC KPQDYWHBSBKWQM-UHFFFAOYSA-N 0.000 description 2
• KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 229960002258 fulvestrant Drugs 0.000 description 2
• 239000001530 fumaric acid Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
• 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• 239000000155 melt Substances 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 230000001617 migratory effect Effects 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000004899 motility Effects 0.000 description 2
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 2
• 229950004847 navitoclax Drugs 0.000 description 2
• JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• 238000011533 pre-incubation Methods 0.000 description 2
• 238000004237 preparative chromatography Methods 0.000 description 2
• 208000037821 progressive disease Diseases 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 238000004749 rapidFire mass spectrometry Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 102200006541 rs121913530 Human genes 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000007790 scraping Methods 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000011125 single therapy Methods 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 210000003802 sputum Anatomy 0.000 description 2
• 208000024794 sputum Diseases 0.000 description 2
• 239000012258 stirred mixture Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000007916 tablet composition Substances 0.000 description 2
• NFAKQWFVEAEEPG-LURJTMIESA-N tert-butyl (4s)-4-methyl-2,2-dioxooxathiazolidine-3-carboxylate Chemical compound C[C@H]1COS(=O)(=O)N1C(=O)OC(C)(C)C NFAKQWFVEAEEPG-LURJTMIESA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• RFGMSGRWQUMJIR-LURJTMIESA-N (2s)-3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound COC[C@@H](C(O)=O)NC(=O)OC(C)(C)C RFGMSGRWQUMJIR-LURJTMIESA-N 0.000 description 1
• FSSJOGPPVNJQGR-AWEZNQCLSA-N (6S)-7-[(3,5-difluorophenyl)methyl]-6-methyl-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound C[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC(F)=CC(F)=C1)C1=C(C)C=NC(NC2=CC=NN2C)=N1 FSSJOGPPVNJQGR-AWEZNQCLSA-N 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• ZLEPJRZWCZMUGA-UHFFFAOYSA-N 1-(bromomethyl)-3-(difluoromethyl)benzene Chemical compound FC(F)C1=CC=CC(CBr)=C1 ZLEPJRZWCZMUGA-UHFFFAOYSA-N 0.000 description 1
• MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
• DDGRAFHHXYIQQR-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1 DDGRAFHHXYIQQR-UHFFFAOYSA-N 0.000 description 1
• 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 description 1
• 108040005121 1-phosphatidylinositol-4-phosphate 5-kinase activity proteins Proteins 0.000 description 1
• NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
• GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
• BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
• ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
• YDEZDCQHDZFRCA-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine-4-carbaldehyde Chemical compound FC(F)(F)C1=NC=CC(C=O)=N1 YDEZDCQHDZFRCA-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• HGCXYDVBTPDXNO-UHFFFAOYSA-N 2-chloro-4-(chloromethyl)-1-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1Cl HGCXYDVBTPDXNO-UHFFFAOYSA-N 0.000 description 1
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 108020005065 3' Flanking Region Proteins 0.000 description 1
• NPAXPTHCUCUHPT-UHFFFAOYSA-N 3,4,7,8-tetramethyl-1,10-phenanthroline Chemical compound CC1=CN=C2C3=NC=C(C)C(C)=C3C=CC2=C1C NPAXPTHCUCUHPT-UHFFFAOYSA-N 0.000 description 1
• JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
• GGTQWWTYUKXFPP-UHFFFAOYSA-N 4-(bromomethyl)-2-chloro-1-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1Cl GGTQWWTYUKXFPP-UHFFFAOYSA-N 0.000 description 1
• SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
• 108020005029 5' Flanking Region Proteins 0.000 description 1
• 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
• QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• ULKKNYNPGDTFDE-UHFFFAOYSA-N 7-[[6-(difluoromethyl)pyridin-2-yl]methyl]-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC(C1=CC=CC(=N1)CN1C(C=2N(CC1)C=C(N=2)C1=NC(=NC=C1C)NC1=CC=NN1C)=O)F ULKKNYNPGDTFDE-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 239000012827 ATM inhibitor Substances 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 description 1
• 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
• 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 102000012936 Angiostatins Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 101100463130 Arabidopsis thaliana PDK gene Proteins 0.000 description 1
• 101100028391 Arabidopsis thaliana PI4KB1 gene Proteins 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 102000036365 BRCA1 Human genes 0.000 description 1
• 108700020463 BRCA1 Proteins 0.000 description 1
• 101150072950 BRCA1 gene Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 229940124291 BTK inhibitor Drugs 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• 108010037003 Buserelin Proteins 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• YOJXVVOUGKCVIH-UHFFFAOYSA-N C(C)OC(=O)C=1N(C=C(N=1)B(O)O)COCC[Si](C)(C)C Chemical compound C(C)OC(=O)C=1N(C=C(N=1)B(O)O)COCC[Si](C)(C)C YOJXVVOUGKCVIH-UHFFFAOYSA-N 0.000 description 1
• 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
• XAPJYDCEXLCSNS-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1N=C(N(C=1)COCC[Si](C)(C)C)C(=O)OCC)Cl Chemical compound ClC1=NC=C(C(=N1)C=1N=C(N(C=1)COCC[Si](C)(C)C)C(=O)OCC)Cl XAPJYDCEXLCSNS-UHFFFAOYSA-N 0.000 description 1
• HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
• 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 101150086923 ERB1 gene Proteins 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 235000014755 Eruca sativa Nutrition 0.000 description 1
• 244000024675 Eruca sativa Species 0.000 description 1
• 241001534160 Escherichia virus Qbeta Species 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 1
• 102100029974 GTPase HRas Human genes 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102100024025 Heparanase Human genes 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 229940127590 IRAK4 inhibitor Drugs 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 102000042838 JAK family Human genes 0.000 description 1
• 108091082332 JAK family Proteins 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
• XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• 229910010084 LiAlH4 Inorganic materials 0.000 description 1
• 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
• 108700041567 MDR Genes Proteins 0.000 description 1
• 230000005723 MEK inhibition Effects 0.000 description 1
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• OIRWOXYZPKJVQM-QRPNPIFTSA-N N[C@H](CN1C(=NC(=C1)C1=NC(=NC=C1)Cl)C(=O)OCC)C.Cl Chemical compound N[C@H](CN1C(=NC(=C1)C1=NC(=NC=C1)Cl)C(=O)OCC)C.Cl OIRWOXYZPKJVQM-QRPNPIFTSA-N 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 102000004459 Nitroreductase Human genes 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 239000012661 PARP inhibitor Substances 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 108030005449 Polo kinases Proteins 0.000 description 1
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 108010066717 Q beta Replicase Proteins 0.000 description 1
• 101150101372 RAF1 gene Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
• 108060006706 SRC Proteins 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• 230000017274 T cell anergy Effects 0.000 description 1
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
• 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000000980 acid dye Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000005042 acyloxymethyl group Chemical group 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000004849 alkoxymethyl group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 238000007844 allele-specific PCR Methods 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940124650 anti-cancer therapies Drugs 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000003432 anti-folate effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000002137 anti-vascular effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 229940127074 antifolate Drugs 0.000 description 1
• 239000013059 antihormonal agent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 239000003719 aurora kinase inhibitor Substances 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
• 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
• 101150048834 braF gene Proteins 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
• 229960002719 buserelin Drugs 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000006721 cell death pathway Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 238000002701 cell growth assay Methods 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• ACONPURZGJUVLW-UHFFFAOYSA-N chloroform;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl ACONPURZGJUVLW-UHFFFAOYSA-N 0.000 description 1
• RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229960002271 cobimetinib Drugs 0.000 description 1
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
• 229960005537 combretastatin A-4 Drugs 0.000 description 1
• HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
• 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000978 cyproterone acetate Drugs 0.000 description 1
• UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
• CRHWEIDCXNDTMO-UHFFFAOYSA-N ditert-butylphosphane Chemical compound CC(C)(C)PC(C)(C)C CRHWEIDCXNDTMO-UHFFFAOYSA-N 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 230000001516 effect on protein Effects 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 230000008995 epigenetic change Effects 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• HJYKVCGAUNFISQ-UHFFFAOYSA-N ethyl 1-(2-aminoethyl)-4-bromoimidazole-2-carboxylate Chemical compound NCCN1C(=NC(=C1)Br)C(=O)OCC HJYKVCGAUNFISQ-UHFFFAOYSA-N 0.000 description 1
• VOKQSLIHOVQPTH-QMMMGPOBSA-N ethyl 1-[(2S)-2-aminopropyl]-4-(2-chloropyrimidin-4-yl)imidazole-2-carboxylate Chemical compound N[C@H](CN1C(=NC(=C1)C1=NC(=NC=C1)Cl)C(=O)OCC)C VOKQSLIHOVQPTH-QMMMGPOBSA-N 0.000 description 1
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 150000005699 fluoropyrimidines Chemical class 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 229950005309 fostamatinib Drugs 0.000 description 1
• GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 238000003505 heat denaturation Methods 0.000 description 1
• 108010037536 heparanase Proteins 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 229960001507 ibrutinib Drugs 0.000 description 1
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000007850 in situ PCR Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 150000008040 ionic compounds Chemical class 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 238000010930 lactamization Methods 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 239000011968 lewis acid catalyst Substances 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 238000007834 ligase chain reaction Methods 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 229950008959 marimastat Drugs 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 108020001162 nitroreductase Proteins 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000012758 nuclear staining Methods 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
• 229960000572 olaparib Drugs 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 238000005580 one pot reaction Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008775 paternal effect Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 101150063097 ppdK gene Proteins 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 239000000092 prognostic biomarker Substances 0.000 description 1
• KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 102000019075 protein serine/threonine/tyrosine kinase activity proteins Human genes 0.000 description 1
• 108040008258 protein serine/threonine/tyrosine kinase activity proteins Proteins 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000010926 purge Methods 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• 108010014186 ras Proteins Proteins 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 229960003522 roquinimex Drugs 0.000 description 1
• 238000002390 rotary evaporation Methods 0.000 description 1
• 102200006537 rs121913529 Human genes 0.000 description 1
• 102200006538 rs121913530 Human genes 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000012798 spherical particle Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 238000004808 supercritical fluid chromatography Methods 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• VJLADRMQGXIGKR-LURJTMIESA-N tert-butyl (4S)-4-methyloxathiazolidine-3-carboxylate Chemical compound C[C@H]1COSN1C(=O)OC(C)(C)C VJLADRMQGXIGKR-LURJTMIESA-N 0.000 description 1
• ALJRPIAYJALVFG-UHFFFAOYSA-N tert-butyl 2,2-dioxooxathiazolidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOS1(=O)=O ALJRPIAYJALVFG-UHFFFAOYSA-N 0.000 description 1
• TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
• PDAFIZPRSXHMCO-LURJTMIESA-N tert-butyl n-[(2s)-1-hydroxypropan-2-yl]carbamate Chemical compound OC[C@H](C)NC(=O)OC(C)(C)C PDAFIZPRSXHMCO-LURJTMIESA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 238000001757 thermogravimetry curve Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical group C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
• UKHQRARQNZOXRL-UHFFFAOYSA-N trimethyltin Chemical compound C[SnH](C)C UKHQRARQNZOXRL-UHFFFAOYSA-N 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
• LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
• 229960001183 venetoclax Drugs 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1